Wall Street brokerages predict that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will announce sales of $1.46 billion for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. The lowest sales estimate is $1.39 billion and the highest is $1.53 billion. Regeneron Pharmaceuticals reported sales of $1.22 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 19.7%. The company is scheduled to announce its next quarterly earnings report on Friday, November 3rd.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year sales of $1.46 billion for the current fiscal year, with estimates ranging from $5.59 billion to $5.98 billion. For the next financial year, analysts expect that the company will post sales of $6.29 billion per share, with estimates ranging from $5.94 billion to $6.59 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same period last year, the business posted $2.82 EPS.

Several research firms recently issued reports on REGN. J P Morgan Chase & Co reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Robert W. Baird reissued a “sell” rating and issued a $408.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $472.00 target price (up from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 target price on the stock in a research report on Wednesday, August 9th. Finally, Leerink Swann reissued an “outperform” rating and issued a $580.00 target price (up from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $496.35.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Expected to Post Quarterly Sales of $1.46 Billion” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/09/regeneron-pharmaceuticals-inc-regn-expected-to-post-quarterly-sales-of-1-46-billion-2.html.

Regeneron Pharmaceuticals (NASDAQ REGN) opened at 471.49 on Friday. The stock has a 50 day moving average price of $483.45 and a 200-day moving average price of $442.76. The stock has a market capitalization of $49.99 billion, a P/E ratio of 47.30 and a beta of 1.65. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55.

In other Regeneron Pharmaceuticals news, EVP Robert J. Terifay sold 21,147 shares of the firm’s stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $468.19, for a total value of $9,900,813.93. Following the completion of the transaction, the executive vice president now owns 72,043 shares of the company’s stock, valued at approximately $33,729,812.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Neil Stahl sold 8,567 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $468.45, for a total transaction of $4,013,211.15. Following the completion of the transaction, the executive vice president now directly owns 44,245 shares of the company’s stock, valued at approximately $20,726,570.25. The disclosure for this sale can be found here. Insiders sold a total of 129,257 shares of company stock valued at $61,745,394 in the last three months. 10.40% of the stock is currently owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Alpha Windward LLC lifted its position in shares of Regeneron Pharmaceuticals by 0.3% during the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares during the last quarter. Concert Wealth Management Inc. lifted its position in shares of Regeneron Pharmaceuticals by 0.4% during the 1st quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 3 shares during the last quarter. Cleararc Capital Inc. lifted its position in shares of Regeneron Pharmaceuticals by 0.3% during the 1st quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock worth $717,000 after purchasing an additional 5 shares during the last quarter. Regentatlantic Capital LLC lifted its position in shares of Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 5 shares during the last quarter. Finally, Capital Planning Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 2.1% during the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 12 shares during the last quarter. 67.96% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.